Global CAR-T Experts
Sign up for a session and connect with a CAR-T expert.
Each session will have a limited number of participants. Please register at your earliest convenience to reserve a seat.
-
Sara Ghorashian, MD, PhD
Hematologist, University College London Institute of Child Health
ALL Small Group Discussion Series:
The Role of Treatment Monitoring and MRD Assessment After CAR-T Cell Infusion
Dr. Ghorashian is a leader in cell therapy research at the University College London Institute of Child Health. She has clinical interests in pediatric malignant hematology and is a co-investigator on two CAR-T cell studies for ALL. She works to improve outcomes with children with high risk or relapsed hematologic malignancies.
-
Prof. Roch Houot, MD, PhD
Head of Hematology Department, University Hospital of Rennes
FL Small Group Discussion Series:
Real-World Experience with CAR-T in FL
Prof. Houot is the head of the Hematology Department at the University Hospital of Rennes in France. His main research interest is novel drug development and immunotherapy (including checkpoint inhibitors, bispecific antibodies, and CAR T-cells) for the treatment of lymphoid malignancies. He continues his work and dedication to investigating CAR T-cells and other innovative gene therapies in oncology.
Previous Sessions:
DLBCL
Identification of Appropriate Patients for CAR-T Cell Therapy
Prof. Peter Bader, MD
Professor of Pediatrics, Johann Wolfgang Goethe University; Head, Stem Cell Transplantation and Immunology, University Hospital, Germany
From 2014 to 2018 Prof. Bader was chairman of the Pediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT). In March 2019 he was Co-President of the 45th Annual EBMT Meeting in Frankfurt. His research is focused in particular on preemptive strategies to prevent relapse after allogeneic stem cell transplantation in children and adolescents with malignant diseases as well as the development and application of innovative cell therapy.
pALL Small Group Discussion Series: the Role of Stem-cell Transplant in the CAR-T Cell Therapy Era
Sara Ghorashian, MD, PhD
Hematologist, University College London Institute of Child Health, United Kingdom
Dr. Ghorashian is a leader in cell therapy research at the University College London Institute of Child Health. She has clinical interests in pediatric malignant hematology and is a co-investigator on two CAR-T cell studies for ALL. She works to improve outcomes with children with high risk or relapsed hematologic malignancies.
Bridging Therapy, Focusing on the Use of Pola-BR (Efficacy and AE)
Satoshi Yoshihara, MD
Associate Professor, Hyogo College of Medicine, Japan
Dr. Yoshihara has broad experience in real-world treatment of patients with CAR-T therapy for lymphoma, ALL, and myeloma. He is particularly interested in investigating approaches aimed to improve real-world CAR-T Therapy outcomes by enhancing T-cell collection efficiency, optimizing bridging therapy, and management of adverse events.
Potential Way to Improve Existing/Approved CAR-T Cell Therapy by In Vivo Immunomodulation
Antonia Müller, MD
Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna, Austria
Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.
Role of Prophylactic and Preemptive Steroids in CAR-T Cell Treatment
Antonia Müller, MD
Professor Cellular Therapy and Transfusion Medicine, MedUni Vienna, Austria
Dr. Müller has participated in a number of pivotal CAR-T trials (including BELINDA). She has a particular interest in sharing her expertise in optimizing the treatments of lymphoma and promoting the importance of interdisciplinary teams in effective disease management.
REGISTRATION IS OPEN.
Register here to participate in upcoming sessions!
This is a paid promotion by Novartis. By registering for this event, you agree that your personal data will be processed in accordance with the Novartis Privacy Policy.